Filing Flows › Pulmonx (LUNG) › Q2 2026 › vs Q1 2026
Pulmonx (LUNG) Q2 2026 vs Q1 2026 (quarter over quarter)
Pulmonx's revenue rose $2.2M (+11%) from $20.6M in Q1 2026 to $22.8M in Q2 2026.
Pulmonx, Q2 2026: revenue $22.8M (-5% year over year), operating margin -39.8%, net loss $10.1M, operating cash flow −$5.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $22.8M | $20.6M | $2.2M | +11% |
| Net loss | $10.1M | $13.7M | −$3.6M | -26% |
| Costs & expenses | $32.8M | $34.2M | −$1.4M | -4% |
| Operating costs | $31.8M | $33.5M | −$1.7M | -5% |
| Interest & other, net | $890K | $549K | $341K | +62% |
| Income tax | $133K | $149K | −$16K | -11% |
| Cost of revenue | $5.0M | $4.5M | $472K | +10% |
| Research & development | $5.0M | $4.9M | $135K | +3% |
| SG&A | $21.8M | $24.1M | −$2.3M | -10% |
| Operating cash sources | $10.1M | $13.7M | −$3.6M | -26% |
| Depreciation | $200K | $200K | $0 | 0% |
| Share-based compensation | $3.7M | $4.1M | −$438K | -11% |
| Working capital & other | $968K | −$779K | $1.7M | — |
| Cash used in operations | $5.2M | $10.1M | −$4.9M | -48% |
| Net loss absorbed | $10.1M | $13.7M | −$3.6M | -26% |
Questions
How much did Pulmonx's revenue grow quarter over quarter in Q2 2026?
Pulmonx's revenue rose $2.2M (+11%) from $20.6M in Q1 2026 to $22.8M in Q2 2026.